Helix BioPharma, ProMab to collaborate on cell-based therapies
Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A
Commercial Banking: June 22nd Edition
Understanding Loss Given Default A Review of Three Approaches
Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy
Helix Biopharma Corp. will collaborate with ProMab Biotechnologies Inc. to develop cell-based therapies.
Under a nonbinding letter of intent, the companies will complete a due diligence and establish a collaboration to develop chimeric antigen receptor T cell therapy for hematological malignancies and solid tumors.